Key factors in the discovery and development of new antiepileptic drugs

Nature Reviews Drug Discovery

Volumn 9, Issue 1, 2010, Pages 68-82

  Bialer, Meir ^a   White, H Steve ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLVALERAMIDE; ANTICONVULSIVE AGENT; BANZEL; BETA1 INTEGRIN; BRIVARACETAM; CARBAMIC ACID 2 (2 CHLOROPHENYL) 2 HYDROXYETHYL ESTER; CARISBAMATE; ESLICARBAZEPINE ACETATE; ETIRACETAM; GABAPENTIN; GABAPENTIN ENACARBIL; GANAXOLONE; HARKOSERIDE; ICA 27243; JZP 4; OXCARBAZEPINE; PERAMPANEL; PIRACETAM; PLACEBO; PREGABALIN; RETIGABINE; RUFINAMIDE; SELETRACETAM; TALAMPANEL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALNOCTAMIDE; VALPROIC ACID; VALROCEMIDE; VIGABATRIN; VOLTAGE GATED SODIUM CHANNEL; YKP 3089; ZEBINEX; ZEBINIX;

ADD ON THERAPY; ANTICONVULSANT ACTIVITY; CLINICAL TRIAL; DISEASE MODEL; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EPILEPSY; HUMAN; HYPONATREMIA; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; LOW DRUG DOSE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; TERATOGENICITY;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG DISCOVERY; DRUG INTERACTIONS; DRUG RESISTANCE; EPILEPSY; HUMANS;

EID: 74049163222     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2997     Document Type: Review

References (129)

1. Bialer, M. et al. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res.73, 1-52 (2007).
2. Bialer, M. et al. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 83, 1-43 (2009).
3. Bialer, M. New antiepileptic drugs (AEDs) in clinical development which are second generation to existing AEDs. Expert Opin. Invest. Drug. 15, 637-647 (2006).
4. Callaghan, B. C., Anand, K., Hesdorffer, D., Hauser, W. A. & French, J. A. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann. Neurol. 62, 382-1289 (2007).
5. Luciano, A. L. & Shorvon, S. D. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann. Neurol., 62, 375-381 (2007).
6. White, H. S. et al. in Antiepileptic Drugs 5th edn (eds Levy, R. H., Mattson, R. H., Meldrum, B. S. & Perucca, E.) 36-48 (Lippincott Williams & Wilkins, New York, 2002).
7. Rogawski, M. A. Diverse mechanisms of antiepileptic drugs in development. Epilepsy Res. 69, 273-284 (2006).
8. Smith, M., Wilcox, K. S. & White, H. S. Discovery of antiepileptic drugs. Neurotherapeutics 4, 12-17 (2007).
9. v/KCNQ/M potassium channels. Curr. Neuro. Neurosci. Rep. 8, 345-352 (2008).
10. Perucca, E., French, J. & Bialer, M. Developing novel antiepileptic drugs (AEDs): challenges, incentives and recent advances. Lancet Neurol. 6, 793-804 (2007).
11. 50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav. 5, 866-872 (2004).
12. Lynch, B. A. et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA 101, 9861-9866 (2004).
13. Gillard, M. Chaterlain, P. & Fuks, B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur. J. Pharmacol. 24, 102-108 (2006).
14. Kaminski, R. M. et al. SV2A protein is a broad-spectrum anticonvulsant agent: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54, 715-720 (2008).
15. Roeloff, R. et al. In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3- yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/7.3) activator in rodent anticonvulsant models. J. Pharmacol. Exper. Ther. 326, 818-828 (2008).
16. Yu, F. H. et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nature Neurosci. 9, 1142-1149 (2006).
17. Vezzani, A., Balosso, S. & Ravizza, T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav. Immun. 2, 797-803 (2008).
18. Marcon, J. et al. Age-dependent vascular changes induced by status epilepticus in rat forebrain: implications for epileptogenesis. Neurobiol. Dis. 34, 121-132 (2009).
19. Ravizza, T. et al. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol. Dis. 29, 142-160 (2008).
20. Zibell, G. et al. Celecoxib prevents seizure-induced up-regulation of endothelial p-glycoprotein in the blood-brain-barrier. Abstract T158 (8th European Congress on Epileptology, Berlin, Germany, 2008).
21. Pitkänen, A. & Sutula, T. P. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol. 1, 173-181 (2002).
22. Fabene, P. et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nature Med. 14 1377-1383 (2008).
23. Kim, J. V., Kang, S. S., Dustin, M. L. & McGavern, D. B. Myelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitis. Nature 457, 191-195 (2009).
24. Ransohoff, R. M. Barrier to electrical storms. Nature 457 155-156 (2009).
25. Medhi, B. et al. Experimentally induced various inflammatory models and seizure: understanding the role of cytokine in rat. Abstract E494 (8th European Congress on Epileptology, Berlin, Germany, 2008).
26. Rao, R. S. et al. Experimentally induced various inflammatory models and seizure: understanding the role of cytokine in rat. Eur. Neuropsychopharmacol. 18, 760-767 (2008).
27. Manent, J. B., Wang, Y., Chang, Y., Paramasivam, M. & LoTurco, J. J. Dcx reexpression reduces subcortical band heterotopia and seizure threshold in an animal model of neuronal migration disorder. Nature Med. 15, 84-90 (2009).
28. Alvarez-Dolado, M. et al. Cortical inhibition modified by embryonic neural precursors grafted into the postnatal brain. J. Neurosci. 26, 7380-7389 (2006).
29. Baraban, S. C. et al. Reduction of seizures by transplantation of cortical GABAergic interneuron precursors into Kv1.1 mutant mice. Proc. Natl Acad. Sci. USA 106, 15472-15477 (2009).
30. Bialer, M. & Yagen, B. Valproic acid-second generation. Neurotherapeutics 4, 130-137 (2007). A comprehensive review of all second-generation drugs to VPA with potential CNS activity.
31. White, H. S. et al. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia 49, 1213-1220 (2008).
32. Perucca, E., Cloyd, J., Critchley, D. & Fuseau, E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 49, 1123-1141 (2008).
33. Wu, C. Y. & Bennet, L. Z. Predicting drug disposition via application of BCS: transport/absorption elimination interplay and development of biopharmaceutics drug disposition classification system. Pharm. Res. 22, 11-23 (2005).
34. Otto, J. F., Kimbal, M. M. & Wilcox, K. S. Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission. Mol. Pharmacol. 61, 921-927 (2002).
35. Rigdon, G. ICA-105665. Antiepileptic Drug Trials X, Syllabus (Coral Gables, Florida, 15-17 Apr 2009).
36. Squillacote, F. Perampanel (E2007). Antiepileptic Drug Trials X, Syllabus (Coral Gables, Florida, 15-17 Apr 2009).
37. Howes, J. F. & Bell, C. B. Talampanel. Neurotherapeutics 4, 126-129 (2007).
38. Rogawski, M. A., Kurzman, R. S., Yamaguhci, S. I. & Li, H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology 40, 28-35 (2001).
39. Gottwald, M. F. & Aminoff, M. J. New frontiers in the pharmacological management of Parkinson's. Drug. Today 44, 531-545 (2008).
40. Eisai Press Release. Status of the E2007 (perampanel) development program-termination of Parkinson's disease clinical development and focus on neuropathic pain and epilepsy indications. Eisai website [online]. http://www.eisai.co.jp/enews/enews200819pdf.pdf (2008).
41. Bialer, M. et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 61, 1-48 (2004).
42. Traynor, B. J. et al. Neuroprotective agents in clinical trials in ALS: a systematic assessment. Neurology 67, 20-27 (2006).
43. Aujla, P. K., Fettell, M. R. & Jaensen, F. Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model. Epilepsia 50 694-701 (2009).
44. Beguin, C., LeTrain, A., Stables, J. P., Voyksner, R. D. & Kohn, H. N-substituted amino acid N-benzylamides: synthesis, anticonvulsant and metabolic activities. Bioorg. Chem. 12, 3079-3096 (2004).
45. Stoehr, T. et al. Lacosamide, a novel anticonvulsant drug, shows efficacy with wide safety margin in rodent models for epilepsy. Epilepsy Res. 74, 147-154 (2007).
46. Errington, A. C., Coyne, L., Stohr, T., Selve, N. & Lees, G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 50, 1016-1029 (2006).
47. Beyrueter, B. K. et al. Lacosamide: a review of preclinical properties. CNS Drug Rev. 13, 21-42 (2007).
48. Czech, T. et al. Reduction of hippocampal collapsing response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem. Res. 28, 2189-2196 (2004).
49. Perucca, E., Yasothan, U., Clincke, G. & Kirkpatrick, P. Lacosamide. Nature Rev. Drug Discov. 7, 973-974 (2008).
50. Shaibani, A., Biton, V., Rauck, R., Koch, B. & Simpson, J. Long term oral lacosamide in a painful diabetic neuropathy: a two-year open-label extension trial. Eur. J. Pain 13, 458-463 (2008).
51. White, H. S. et al. The novel investigational neuromodulator RWJ-333369 displays a broad-spectrum anticonvulsant profile in rodent seizure and epilepsy models. Epilepsia Abstr. 37, 320 (2006).
52. Francois, J., Boehrer, A. & Nehlig, A. Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GEARS and the audiogenic Wistar AS. Epilepsia 49, 393-399 (2008).
53. Grabenstatter, H. & Dudek, F. E. A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainite-induced epilepsy. Epilepsia 49, 1787-1794 (2008).
54. Deshpande, L. S., Nagarkatti, N., Sombati, S. & DeLorenzo, R. J. The novel antiepileptic drug carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure discharges and blocking sustained repetitive firing in cultured hippocampal neurons. Epilepsy Res. 79, 158-165 (2008).
55. Liu, Y. et al. Carisbamate, a novel neuromodulator, inhibits voltage-gated, rat brain sodium channels. Epilepsy Res. 83, 66-72 (2009).
56. Whalley, B. J., Stephens, G. J. & Constanti, A. Investigation of the effects of the novel anticonvulsant compound carisbamate (RWJ-333369) on rat piriform cortical neurons in vitro. Br. J. Pharmacol. 156, 994-1008 (2009).
57. Yao, C., Doose, D. R., Novak, G. & Bialer, M. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369, following single and multiple dosing to humans. Epilepsia 47, 1822-1829 (2006).
58. Sargentini-Maier, M. L. et al. The pharmacokinetics and CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral dose in healthy males. Br. J. Clin. Pharmacol. 63, 680-688 (2007).
59. 14C-brivaracetam, a novel SV2A ligand, in healthy males. Drug Metab. Dispos. 26, 36-45 (2008).
60. Rolan, P., Sargentini-Maier, M. L., Pigeolet, E. & Stockis, A. The pharmacokinetics & CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral dose in healthy men. Br. J. Clin. Pharmacol. 66, 71-75 (2008).
61. th edn (eds Levy, R. H., Mattson, R. H., Meldrum, B. S. & Perucca, E.) 419-427 (Lippincott Williams & Wilkins, New York, 2002).
62. Kenda, B. et al. Discovery of 4-substituted pyrrolidone butanamides as agents with significant antiepileptic activities. J. Med. Chem. 47, 530-549 (2004).
63. Volosov, A. et al. Enantioselective pharmacokinetics of 10-hydroxycarbazepine following oral administration of oxcarbazepine to healthy Chinese subjects. Clin. Pharmacol. Ther. 66, 547-553 (1999).
64. Bialer, M. in Antiepielptic Drugs 5th edn (eds Levy, R. H., Mattson, R. H., Meldrum, B. S. & Perucca, E.) 459-465 (Lippincott Williams & Wilkins, New York, 2002).
65. Elger, C., Halász, P., Maia, J., Almeida, L. & Soares-da-Silva, P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 50, 454-463 (2009).
66. rd edn (eds Shorvon, S., Perucca, E. & Engel, J.) 485-498 (Wiley-Blackwell, Oxford, 2009).
67. Souppart, C. et al. Pharmacokinetics of licarbazepine in healthy volunteers: single and multiple oral doses and effect of food. J. Clin. Pharmacol. 48, 563-569 (2008).
68. Tucker, G. T. Chiral switches. Lancet 355, 1085-1087 (2000).
69. Meador, K. J. et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 360, 1597-1605 (2009).
70. Isoherranen, N. et al. Characterization of the anticonvulsant activity and pharmacokinetics of propylisopropyl acetamide and its enantiomers. Br. J. Pharmacol. 138, 602-613 (2003).
71. Isoherranen, N. et al. Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy. Pharm. Res. 20, 1293-1301(2003).
72. Winkler, I. et al. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model for neuropathic pain. Br. J. Pharmacol. 146, 198-208 (2005). (Pubitemid 43079959)
73. Kaufmann, D. et al. Evaluation of enantioselective antiallodynic profile and pharmacokinetics of propylisopropylacetamide, a chiral isomer of valproic acid amide. Neuropharmacology 54, 699-707 (2008).
74. Applebaum, J., Gayduk, J., Agam, G., Bersudsky, Y. & Belmaker, R. H. Valnoctamide as valproate substitute with low teratogenic potential: double blind controlled clinical trial. Bipolar Disord. 7, 30 (2005).
75. Winkler, I. et al. Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model for neuropathic pain. Neuropharmacology 49, 1110-1120 (2005). (Pubitemid 41608635)
76. Sobol, E., Bialer, M. & Yagen, B. Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J. Med. Chem. 47, 4316-4326 (2004).
77. Shimshoni, J. et al. The effect of CNS-active valproic acid constitutional isomers, cyclopropyl analogues and amide derivatives on neuronal growth cone behavior. Mol. Pharmacol. 71, 884-892 (2007).
78. Vajda, F. I. et al. Critical relationship between sodium valproate dose and human teratogenicity; results of the Australian register of anti-epileptic drugs in pregnancy. J. Clin. Neurosci. 11, 854-858 (2004).
79. Meador, K. J. Effect of in utero antiepileptic drug exposure. Epilepsy Curr. 8, 144-147 (2008).
80. Cundy, K. C. et al. XP13512 [±1-([(α-isobutanoyl-oxyethoxy) carbonyl]aminoethyl)-1cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporter. J. Pharmacol. Exp. Ther. 31, 315-323 (2004).
81. Cundy, K. C. et al. XP13512 [±1-([(α-isobutanoyl-oxyethoxy) carbonyl]aminoethyl)-1cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J. Pharmacol. Exp.Ther. 3 11, 324-333 (2004).
82. Cundy, K. C. et al. Clinical pharmacokinetics of XP13512 a novel transported prodrug of gabapentin prodrug. J. Clin. Pharmacol. 48, 1378-1388 (2008).
83. Foreman, M. et al. In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models of anticonvulsant, antimania and antidepressant activity. Phramacol. Biochem. Behav. 89, 523-534 (2008).
84. White, H. S. & Smith, M. D. in Advanced Therapy in Epilepsy (eds Wheless, J. W., Willmore, L. J. & Brumback, R. A.) 226-232 (B. C. Decker, Hamilton, 2009).
85. Guerrini, R. et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 39, 508-512 (1998).
86. Kalume, F., Yu, F. H., Westenbroek, R. E., Scheuer, T. & Catterall, W. A. Reduced sodium current in Purkinje neurons from Nav1.1 mutant mice: implications for ataxia in severe myoclonic epilepsy in infancy. J. Neurosci. 27, 11065-11074 (2007).
87. Oakley, J. C., Kalume, F., Yu, F. H., Scheuer, T. & Catterall, W. A. Temperature-and age-dependent seizures in a mouse model of severe myoclonic epilepsy in infancy. Proc. Natl Acad. Sci. USA 106, 3994-3999 (2009).
88. Klitgaard, H., Matagne, A., Gobert, J. & Wülfert, E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 353, 191-206 (1998).
89. Matagne, A. & Klitgaard, H. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res. 31, 59-71 (1998).
90. Gower, A. J., Hirsch, E., Boehrer, A., Noyer, M. & Marescaux, C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 22, 207-213 (1995).
91. Löscher, W. & Hönack, D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 232, 147-158 (1993).
92. Gower, A. J., Noyer, M., Verloes, R., Gobert, J. & Wülfert, E. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. 222, 193-203 (1992).
93. Lothman, E. W., Salerno, R. A., Perlin, J. B. & Kaiser, D. L. Screening and characterization of antiepileptic drugs with rapidly hippocampal seizures in rats. Epilepsy Res. 2, 367-379 (1988).
94. Löscher, W. in Models of Seizures and Epilepsy (eds Pitkanen, A., Schwartzkroin, P. A. & Moshe, S. L.) 551-567 (Elsevier, New York, 2006).
95. Loscher, W., Rundfeldt, C. & Honack, D. Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res. 15, 207-219 (1993).
96. Rundfeldt, C. & Loscher, W. Anticonvulsant efficacy and adverse effects of phenytoin during chronic treatment in amygdala-kindled rats. J. Pharmacol. Exp. Ther. 266, 216-223 (1993).
97. Postma, T., Krupp, E., Li, X. L., Post, R. M. & Weiss, S. R. Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy. Epilepsia 41, 1514-1521 (2000).
98. Srivastava, A., Woodhead, J. H. & White, H. S. Effect of lamotrigine, carbamazepine and sodium valproate on lamotrigine-resistant kindled rats. Epilepsia 44 (Suppl. 9), 42 (2003).
99. Srivastava, A., Franklin, M. R., Palmer, B. S. & White, H. S. Carbamazepine, but not valproate, displays pharmaco-resistance in lamotrigine-resistant amygdala kindled rats. Epilepsia 45 (Suppl. 7), 12 (2004).
100. Srivastava, A. & White, H. S. Retigabine decreases behavioral and electrographic seizures in the lamotrigine-resistant amygdala kindled rat model of pharmacoresistant epilepsy. Epilepsia 46 (Suppl. 8), 217-218 (2005).
101. Barton, M. E., Klein, B. D., Wolf, H. H. & White, H. S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 47, 217-227 (2001).
102. Brandt, C., Volk, H. A. & Loscher, W. Striking differences in individual anticonvulsant response to phenobarbital in rats with spontaneous seizures after status epilepticus. Epilepsia 45, 1488-1497 (2004).
103. Glien, M., Brandt, C., Potschka, H. & Loscher, W. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 43, 350-357 (2002).
104. Leite, J. P. & Cavalheiro, E. A. Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res. 20, 93-104 (1995).
105. Grabenstatter, H. L. & Dudek, F. E. The effect of carbamazepine on spontaneous seizures in freely-behaving rats with kainate-induced epilepsy. Epilepsia 46 (Suppl. 8), 287 (2005).
106. Grabenstatter, H. L., Ferraro, D. J., Williams, P. A., Chapman, P. L. & Dudek, F. E. Use of chronic epilepsy models in antiepileptic drug discovery: the effect of topiramate on spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 46, 8-14 (2005).
107. van Vliet, E. A. et al. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 47, 672-680 (2006).
108. Smyth, M. D., Barbaro, N. M. & Baraban, S. C. Effects of antiepileptic drugs on induced epileptiform activity in a rat model of dysplasia. Epilepsy Res. 50, 251-264 (2002).
109. Rho, J. M. & Sankar, R. The pharmacologic basis of antiepileptic drug action. Epilepsia 40, 1471-1483 (1999).
110. V1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J. Neurosci. 27, 5903-5914 (2007).
111. Davis, T. H., Chen, C. & Isom, L. L. Sodium channel β1 subunit neurite outgrowth in cerebellar granule neurons. J. Biol. Chem. 279, 51424-51432 (2004).
112. Planells-Cases, R. et al. Neuronal death and perinatal lethality in voltage-gated sodium channel alpha(II)-deficient mice. Biophys. J. 78, 2878-2891 (2000).
113. Kearney, J. A. et al. A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities. Neuroscience 102, 307-317 (2001).
114. 2+ current is a molecular determinant of excitatory effects of GABA in adult sensory neurons. Mol. Cell Neurosci. 36, 293-303 (2007).
115. Escayg, A., Jones, J. M., Kearney, J. A., Hitchcock, P. F. & Meisler, M. H. Calcium channel β4 (CACNB4): human ortholog of the mouse epilepsy gene lethargic. Genomics 50, 14-22 (1998).
116. Burgess, D. L. & Noebels, J. L. Single gene defects in mice: the role of voltage-dependent calcium channels in absence models. Epilepsy Res. 36, 111-122 (1999).
117. Watanabe, H. et al. Disruption of the epilepsy KCNQ2 gene results in neural hyperexcitability. J. Neurochem. 75, 28-33 (2000).
118. Yang, Y. et al. Spontaneous deletion of epilepsy gene orthologs in a mutant mouse with a low electroconvulsive threshold. Hum. Mol. Genet. 12, 975-984 (2003).
119. Singh, N. A. et al. Mouse models of human KCNQ2 and KCNQ3 mutations for benign familial neonatal convulsions show seizures and neuronal plasticity without synaptic reorganization. J. Physiol. 586, 3405-3423 (2008).
120. V1.1 potassium channel causes epilepsy in mice. Neuron 20, 809-819 (1998).
121. Guo, W. et al. Targeted deletion of Kv4.2 eliminates I(to,f) and results in electrical and molecular remodeling, with no evidence of ventricular hypertrophy or myocardial dysfunction. Circ. Res. 97, 1342-1350 (2005).
122. Sur, C. et al. Loss of the major GABAA receptor subtype in the brain is not lethal in mice. J. Neurosci. 21, 3409-3418 (2001).
123. A receptor α1 subunit deletion prevents developmental changes of inhibitory synaptic currents in cerebellar neurons. J. Neurosci. 21, 3009-3016 (2001).
124. Tan, H. O. et al. Reduced cortical inhibition in a mouse model of familial childhood absence epilepsy. Proc. Natl Acad. Sci. USA 104, 17536-17541 (2007).
125. Manfredi, I. et al. Expression of mutant β2 nicotinic receptors during development is crucial for epileptogenesis. Hum. Mol. Genet. 18, 1075-1088 (2009).
126. 4 nicotinic acetylcholine receptor subunit knockout mice. Neuropharmacology 43, 55-64 (2002).
127. Klaassen, A. et al. Seizures and enhanced cortical GABAergic inhibition in two mouse models of human autosomal dominant nocturnal frontal lobe epilepsy. Proc. Natl Acad. Sci USA 103, 19152-19157 (2006).
128. Teper, Y. et al. Nicotine-induced dystonic arousal complex in a mouse line harboring a human autosomal-dominant nocturnal frontal lobe epilepsy mutation. J. Neurosci. 27, 10128-10142 (2007).
129. Bersudsky, Y. et al. Valnoctamide as a valproate substitute with low teratogenic potential in mania: double-blind controlled clinical trial. Bipolar Disord. (in the press).